DIAMIR, LLC
Blood-based microRNA biomarker assay for detection and monitoring of Rett syndrome pathophysiology
- Sector
- Medtech
- Headquarters
- Princeton, NJ
- Total capital
- $8.8M
- Federal grants
- $8.8M
- 12 awards · 2015–2022
- Rank in peer group#14 of 112
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 14 pending · first 2019
- Rank in peer group#8 of 112
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's Disease$625K
- Federal grantHealth and Human S · Phase I · Circulating Organ-enriched microRNAs as biomarkers of Rett Syndrome$111K
- Federal grantHealth and Human S · Phase II · Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's Disease$1.5M
- Federal grantHealth and Human S · Phase I · Circulating Organ-enriched microRNAs as biomarkers of Rett Syndrome$499K
- Federal grantHealth and Human S · Phase II · Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's Disease$1.3M
- Federal grantHealth and Human S · Phase II · Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's disease$345K
- Federal grantHealth and Human S · Phase II · Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's disease$946K
Show 5 earlier federal awards
- Federal grantHealth and Human S · Phase II · Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's disease$910K
- Federal grantHealth and Human S · Phase II · Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's disease$917K
- Federal grantHealth and Human S · Phase I · Circulating organ-enriched microRNAs as biomarkers of aging$225K
- Federal grantHealth and Human S · Phase II · Early detection of Alzheimer's (MCI stage): Analysis of plasma cell-free miRNA$779K
- Federal grantHealth and Human S · Phase II · Early detection of Alzheimer's (MCI stage): Analysis of plasma cell-free miRNA$716K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grants#14 · top 13%
- Granted patents#8 · top 7%
- Linked publications#7 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 6 granted of 20- GrantedMethods Of Using Mirnas From Bodily Fluids For Detection And Differentiation Of Neurodegenerative DiseasesUSPTOUS 11,149,313
- GrantedMethods Of Using Mirnas From Bodily Fluids For Detection And Monitoring Of Parkinson's Disease (pd)USPTOUS 11,098,362
- GrantedMETHODS OF USING miRNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEVELOPMENTAL DISORDERSUSPTOUS 10,975,436
Show all 20 patent records
- Methods Of Using Mirnas From Bodily Fluids For Detection And Differentiation Of Neurodegenerative DiseasesOct 19, 2021 · US 11,149,313Granted
- Methods Of Using Mirnas From Bodily Fluids For Detection And Monitoring Of Parkinson's Disease (pd)Aug 24, 2021 · US 11,098,362Granted
- METHODS OF USING miRNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEVELOPMENTAL DISORDERSApr 13, 2021 · US 10,975,436Granted
- Mirna-based Methods For Detecting And Monitoring AgingSep 22, 2020 · US 10,781,487Granted
- Mirna-based Universal Screening Test (ust)Nov 12, 2019 · US 10,472,681Granted
- METHODS OF USING miRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD)Apr 2, 2019 · US 10,246,747Granted
- Methods Of Using Small Rna From Bodily Fluids For Diagnosis And Monitoring Of Neurodegenerative DiseasesDec 4, 2014 · Application 14146275Pending
- METHODS OF USING miRNAs FROM BODILY FLUIDS FOR DETECTION AND DIFFERENTIATION OF NEURODEGENERATIVE DISEASESApplication 62310979Pending
- METHODS OF USING miRNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEVELOPMENTAL DISORDERSApplication 62274999Pending
- Methods Of Using Mirnas From Bodily Fluids For Detection And Monitoring Of Parkinson's Disease (pd)Application PCTUS2014065959Pending
- METHODS OF USING miRNAs FROM BODILY FLUIDS FOR DETECTION AND MONITORING OF PARKINSON'S DISEASE (PD)Application 61935806Pending
- METHOD OF SELECTING BIOMARKER miRNA PAIRS FOR SCREENING, DIAGNOSTIC AND MONITORING TESTSApplication 61905703Pending
- Mirna-based Universal Screening Test (ust)Application PCTUS2012034098Pending
- Methods Of Using Mirna From Bodily Fluids For Early Detection And Monitoring Of Mild Cognitive Impairment (mci) And Alzheimer's Disease (ad)Application PCTUS2012034025Pending
- miRNA-BASED METHODS FOR DETECTING AND MONITORING AGINGApplication 62536320Pending
- METHODS OF USING miRNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEVELOPMENTAL DISORDERSApplication 62529372Pending
- Methods Of Using Mirnas From Bodily Fluids For Detection And Differentiation Of Neurodegenerative DiseasesApplication PCTUS2017023470Pending
- Methods Of Using Mirna From Bodily Fluids For Diagnosis And Monitoring Of Neurodevelopmental DisordersApplication PCTUS2017012258Pending
- METHODS OF USING miRNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEVELOPMENTAL DISORDERSApplication 62396577Pending
- METHODS OF USING miRNAs FROM BODILY FLUIDS FOR DETECTION AND DIFFERENTIATION OF NEURODEGENERATIVE DISEASESApplication 62365663Pending
Recent research by its founders
- Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens20260 cites
- Classifier algorithms to characterize various stages of Alzheimer’s disease based on analysis of circulating brain‐enriched and inflammation‐associated microRNAs20240 cites
- Analytical Validation of a Novel MicroRNA Panel for Risk Stratification of Cognitive Impairment20234 cites
Related companies, and why
- Ropana Vascular Inc.Similar federal contract value in Medtech · null in contracts
- BIODEVEK INCSimilar federal contract value in Medtech · null in contracts
- EMBEDRF, LLCSimilar federal contract value in Medtech · null in contracts
- POLYMER EXPLORATION GROUP, LLCSimilar federal contract value in Medtech · null in contracts
- VIZMA LIFE SCIENCES INCSimilar federal contract value in Medtech · null in contracts
- FREE TO FEED, INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .